All In Biotech

Drug Trial Radar · NCT07766499

A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of THB335 in Adult Participants With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Standard-of-Care Treatment

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Dec 31, 2027

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Calixis Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment. The study includes a Screening Period of up to 4 weeks, a 12-week Treatment Period, and a 4-week Follow-Up Period, for a total participant duration of approximately 20 weeks.

Conditions

  • Chronic Spontaneous Urticaria (CSU)
  • Chronic Idiopathic Urticaria

Interventions

  • THB335 Lower DoseDrug

    THB335 is an orally administered capsule added to a stable background regimen of a second generation H1 antihistamine.

  • THB335 Higher DoseDrug

    THB335 is an orally administered capsule added to a stable background regimen of a second generation H1 antihistamine.

  • PlaceboDrug

    Placebo is an orally administered capsule added to a stable background regimen of a second generation H1 antihistamine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12Time frame: Baseline and Week 12

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Calixis Study Site

    Pasadena, California · Recruiting

  • Calixis Study Site

    Ventura, California · Recruiting

  • Calixis Study Site

    Walnut Creek, California · Recruiting

  • Calixis Study Site

    Altamonte Springs, Florida · Recruiting

  • Calixis Study Site

    Tampa, Florida · Recruiting

  • Calixis Study Site

    Atlanta, Georgia · Recruiting

  • Calixis Study Site

    Boise, Idaho · Recruiting

  • Calixis Study Site

    Baton Rouge, Louisiana · Recruiting

  • Calixis Study Site

    White Marsh, Maryland · Recruiting

  • Calixis Study Site

    Wildwood, Missouri · Recruiting

  • Calixis Study Site

    Asheville, North Carolina · Recruiting

  • Calixis Study Site

    Smyrna, Tennessee · Recruiting

  • Calixis Study Site

    Austin, Texas · Recruiting

  • Calixis Study Site

    Houston, Texas · Recruiting

  • Calixis Study Site

    Prosper, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.